The compounds Walk the Line offers today — and a plain-language look at the FDA review shaping what comes next.
Sheena Eversole, MSN, AAPRN, FNP-BC · Autonomous Nurse Practitioner · Practicing Medicine Since 2004
Book NowTwo regenerative-wellness compounds are available at Walk the Line right now, compounded through our trusted pharmacies. Every plan starts with a telemedicine appointment with Sheena — she'll confirm whether an option fits your goals.
A coenzyme found in every living cell — a cofactor your body relies on for energy metabolism, DNA repair, and hundreds of other cellular reactions, with natural levels that decline as we age, per a peer-reviewed review in Aging and Disease. In a wellness setting it's used to support energy, focus, and healthy aging — benefits still being studied and not FDA-approved claims. Individual results vary.
A naturally occurring peptide first isolated from human plasma, where its level also falls with age; studied for roles in skin regeneration, collagen production, and wound healing, per a peer-reviewed review in BioMed Research International. Most often used to support skin firmness, elasticity, and repair. Individual results vary.
Dissolve-under-the-tongue troches, compounded and shipped to you.
Applied directly to the skin.
Each of the seven compounds below is currently under consideration by FDA's Pharmacy Compounding Advisory Committee for addition to the Category 1 (permitted) 503A compounding list.
BPC-157 is one of the seven peptides FDA's Pharmacy Compounding Advisory Committee is considering this month for the Category 1 (permitted) 503A compounding list. FDA's review evaluated its use for ulcerative colitis.
TB-500 is one of the seven peptides under consideration this month. FDA's review evaluated its use for wound healing.
KPV is one of the seven peptides under consideration this month. FDA's review evaluated its use for wound healing and inflammatory conditions.
MOTs-C is one of the seven peptides under consideration this month. FDA's review evaluated its use for obesity and osteoporosis.
Emideltide — also known as delta sleep-inducing peptide, or DSIP — is one of the seven peptides under consideration this month. FDA's review evaluated its use for opioid withdrawal, chronic insomnia, and narcolepsy.
Semax is one of the seven peptides under consideration this month. FDA's review evaluated its use for cerebral ischemia, migraine, and trigeminal neuralgia.
Epitalon is one of the seven peptides under consideration this month. FDA's review evaluated its use for insomnia.
Federal law only lets a compounding pharmacy prepare a medication from a “bulk drug substance” that meets specific conditions — one of which is appearing on FDA's Section 503A Bulks List, the product of a public review run through FDA's Pharmacy Compounding Advisory Committee (PCAC), according to FDA's own notice of this meeting. Substances nominated for that list fall into three categories, according to legal analysis of FDA's compounding guidance from the FDA Law Blog: Category 1, where FDA has enough safety information to permit compounding; Category 2, where FDA has identified a significant safety risk and compounding is not permitted; and Category 3, where FDA doesn't yet have enough information to decide either way.
What a Category 1 designation is not:
All seven of these peptides were removed from FDA's Category 2 list — the significant-safety-risk list, where compounding isn't permitted — in April 2026. But removal from Category 2 does not put a substance on Category 1: per the FDA Law Blog, none of the seven has ever been on Category 1. That's exactly what this meeting is deciding. The Committee's role itself is advisory — it makes a recommendation, and FDA makes the final call.
The meeting hasn't happened yet.FDA's Pharmacy Compounding Advisory Committee meets July 23–24, 2026, at FDA's White Oak campus to consider BPC-157, KPV, TB-500, and MOTs-C on the first day, and Emideltide (DSIP), Semax, and Epitalon on the second. We'll update this page once the outcome is known.
A second PCAC meeting focused on five more peptides — including GHK-Cu, which Walk the Line already offers in troche and topical form (see Available Now above) — is expected before the end of February 2027.
Peptide therapy isn't a fit for every goal, and the right compound — if any — depends on a real conversation about your health history, not a self-assessment. Book a telemedicine appointment and Sheena will walk through whether peptide therapy makes sense for you, and which option fits your goals.
Legal availability of any specific peptide is an active, evolving area of federal regulation — Sheena will confirm exactly what's currently offered at your appointment, not what a page written weeks or months earlier assumed.
Peptide therapy is delivered by telemedicine appointment — no office visit required. Labs, when needed, can be completed at a local lab near you.
Peptide therapy is available by telemedicine across every state where Sheena is licensed:
Peptides are short chains of amino acids that act as messengers in the body, and peptide therapy uses specific peptides to support things like recovery, metabolic health, or cognitive and energy support. At Walk the Line, peptide therapy is guided by a real evaluation with Sheena, not a one-size-fits-all protocol.
Most peptides are given by injection, since they tend to break down before reaching the bloodstream through other routes — though some are available as oral or topical options depending on the compound. Sheena will confirm the right administration method for your plan.
Yes — peptide therapy at Walk the Line is delivered by telemedicine appointment across every state where Sheena is licensed.
That starts with a real telemedicine appointment with Sheena — a conversation about your goals and history, not a self-assessment. She'll walk you through which options make sense for you.
It means FDA has reviewed a bulk drug substance and found enough safety information to permit compounding pharmacies to prepare it under Section 503A of federal law. It's a legal and manufacturing determination — not FDA drug approval, not a finding that the substance is clinically proven effective for any specific use, and not related to insurance coverage.
Not currently. None of the seven peptides FDA's Pharmacy Compounding Advisory Committee is reviewing on July 23–24, 2026 are part of Walk the Line's program today — they're covered on this page for general regulatory awareness, not because they're offered here. We'll update this page if that changes.